Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA

[1]  E. Losina,et al.  The Potential Economic Benefits of Improved Postfracture Care: A Cost‐Effectiveness Analysis of a Fracture Liaison Service in the US Health‐Care System , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  S. Roux,et al.  Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach , 2013, The Journal of Rheumatology.

[3]  P. Geusens,et al.  Optimizing fracture prevention: the fracture liaison service, an observational study , 2013, Osteoporosis International.

[4]  S. Tan,et al.  Secondary prevention of osteoporotic fractures—an “OPTIMAL” model of care from Singapore , 2013, Osteoporosis International.

[5]  Simon G A Brown.  Treatment failure in osteoporosis. , 2012, Menopause international.

[6]  S. Silverman,et al.  Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  L. Lix,et al.  A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving , 2012, Osteoporosis International.

[8]  L. Melton,et al.  Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status , 2012, Osteoporosis International.

[9]  L. Ray,et al.  Treatment for older men with fractures , 2012, Osteoporosis International.

[10]  A. Roddam,et al.  Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database , 2012, Menopause.

[11]  A. LaCroix,et al.  Predicting fractures in an international cohort using risk factor algorithms without BMD , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  J. Abarca,et al.  Analysis of the Comparative Effectiveness of 3 Oral Bisphosphonates in a Large Managed Care Organization: Adherence, Fracture Rates, and All-Cause Cost , 2011, Journal of managed care pharmacy : JMCP.

[13]  R. Goeree,et al.  The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women , 2011, BMC musculoskeletal disorders.

[14]  C. Cooper,et al.  Interpretation and use of FRAX in clinical practice , 2011, Osteoporosis International.

[15]  D. Beaton,et al.  Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: A qualitative study , 2011, BMC musculoskeletal disorders.

[16]  S. Cummings,et al.  Secular trends in the incidence of hip and other osteoporotic fractures , 2011, Osteoporosis International.

[17]  B. Mcgowan,et al.  Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures , 2011, European Journal of Clinical Pharmacology.

[18]  P. Cram,et al.  Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system , 2011, Osteoporosis International.

[19]  P. Lüthje,et al.  Undertreatment of osteoporosis following hip fracture in the elderly. , 2009, Archives of gerontology and geriatrics.

[20]  T. Weiss,et al.  Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) , 2009, Osteoporosis International.

[21]  P. Delmas,et al.  Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application , 2008, Osteoporosis International.

[22]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[23]  Martha Timmer,et al.  Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis , 2007, Annals of Internal Medicine.

[24]  J. Eisman,et al.  Residual Lifetime Risk of Fractures in Women and Men , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  A. Tosteson,et al.  Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  O. Johnell,et al.  Multinational survey of osteoporotic fracture management , 2005, Osteoporosis International.

[27]  D. Beaton,et al.  Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review , 2004, Osteoporosis International.

[28]  S. Sen,et al.  Undertreatment with anti-osteoporotic drugs after hospitalization for fracture , 2004, Osteoporosis International.

[29]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[30]  D. Beaton,et al.  Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program , 2013, Osteoporosis International.

[31]  L. Lix,et al.  Fracture risk assessment without bone density measurement in routine clinical practice , 2011, Osteoporosis International.

[32]  M. Intorcia,et al.  GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates , 2011, Osteoporosis International.

[33]  J. Skedros,et al.  Knowledge and opinions of orthopaedic surgeons concerning medical evaluation and treatment of patients with osteoporotic fracture. , 2006, The Journal of bone and joint surgery. American volume.